[{"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-001", "question": "A 38-year-old man undergoes evaluation for chronic diarrhea and weight loss. Small bowel biopsy reveals villous atrophy with increased intraepithelial lymphocytes. Despite strict gluten-free diet adherence confirmed by negative tissue transglutaminase antibodies for 18 months, symptoms persist. Repeat biopsy shows persistent villous atrophy with aberrant intraepithelial lymphocytes lacking surface CD3 but expressing cytoplasmic CD3, CD7, and CD103, with loss of CD8. T-cell receptor gene rearrangement studies show a monoclonal population. Which therapeutic approach offers the best chance of inducing remission before consideration of autologous stem cell transplantation?", "options": ["Budesonide 9 mg daily", "Cladribine-based chemotherapy", "Infliximab induction and maintenance", "Azathioprine 2.5 mg/kg daily", "Mesalamine 4.8 g daily"], "answer": "B", "answer_index": 1, "explanation": "This patient has Type II refractory celiac disease (RCD II), characterized by aberrant intraepithelial lymphocytes with the described immunophenotype (surface CD3-negative, cytoplasmic CD3-positive, CD8 loss) and monoclonal TCR rearrangement. RCD II has high risk of progression to enteropathy-associated T-cell lymphoma. Cladribine (2-CdA), a purine analog, has shown the best response rates (approximately 40-50%) in inducing histologic and clinical remission in RCD II and serves as a bridge to autologous stem cell transplantation. Steroids, immunomodulators, and biologics used in RCD I are ineffective in RCD II.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "B", "model_outputs": "The patient presents with chronic diarrhea and weight loss, initially suggestive of celiac disease. However, despite strict adherence to a gluten-free diet and negative serology, symptoms persist. The repeat biopsy reveals persistent villous atrophy along with aberrant intraepithelial lymphocytes. The immunophenotype of these lymphocytes is crucial: lack of surface CD3 but expression of cytoplasmic CD3, CD7, and CD103, with loss of CD8. Furthermore, T-cell receptor gene rearrangement studies show a monoclonal population. These findings are diagnostic markers for Enteropathy-Associated T-cell Lymphoma (EATL), a rare and aggressive T-cell lymphoma that arises from intraepithelial lymphocytes in the small intestine, often occurring in individuals with a history of celiac disease.\n\nThe question asks for the best therapeutic approach to induce remission *before* considering autologous stem cell transplantation. This indicates a need for systemic treatment of the lymphoma.\n\nLet's evaluate the options:\nA. Budesonide: A corticosteroid used for inflammatory conditions, not directly effective against lymphoma.\nB. Cladribine-based chemotherapy: Cladribine is a purine analog chemotherapy agent effective against lymphoid malignancies. It is a standard component of treatment regimens for various T-cell lymphomas. Given the diagnosis of EATL, chemotherapy is the appropriate first-line systemic therapy.\nC. Infliximab: A TNF-alpha inhibitor used for inflammatory bowel disease. It is not a treatment for lymphoma.\nD. Azathioprine: An immunosuppressant. While used in some inflammatory conditions and sometimes associated with increased lymphoma risk, it is not a primary treatment for established lymphoma.\nE. Mesalamine: A 5-ASA derivative used for inflammatory bowel disease. It is not effective against lymphoma.\n\nTherefore, cladribine-based chemotherapy is the most appropriate therapeutic approach for inducing remission of EATL before considering more intensive treatments like stem cell transplantation.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-002", "question": "A 71-year-old man with COPD GOLD stage III is hospitalized for acute exacerbation. On day 3, despite antibiotics, systemic corticosteroids, and scheduled bronchodilators, he remains dyspneic with respiratory rate 28/min, accessory muscle use, and ABG showing pH 7.31, PaCO2 58 mmHg, PaO2 55 mmHg on 4L nasal cannula. He is alert and cooperative. Bilevel positive airway pressure (BiPAP) is initiated at IPAP 12/EPAP 5 cm H2O. After 2 hours, repeat ABG shows pH 7.29, PaCO2 62 mmHg. He remains tachypneic but is tolerating the mask. What is the most appropriate next step?", "options": ["Increase IPAP to 18 cm H2O and reassess in 1-2 hours", "Proceed with endotracheal intubation and mechanical ventilation", "Add heliox (helium-oxygen mixture) to the BiPAP circuit", "Switch to high-flow nasal cannula at 60 L/min", "Increase EPAP to 10 cm H2O while maintaining IPAP"], "answer": "A", "answer_index": 0, "explanation": "The patient has acute hypercapnic respiratory failure from COPD exacerbation with initial NIV settings that are inadequate (worsening hypercapnia). The driving pressure (IPAP-EPAP = 7 cm H2O) is insufficient for adequate ventilation. Increasing IPAP to 18 cm H2O (driving pressure 13 cm H2O) will augment tidal volume and improve CO2 clearance. Intubation (B) is premature as he is tolerating NIV and is not deteriorating clinically. Heliox (C) reduces airway resistance but doesn't address ventilation. HFNC (D) provides less ventilatory support than BiPAP for hypercapnic failure. Increasing EPAP alone (E) would reduce driving pressure further, worsening ventilation.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "A", "model_outputs": "The patient is suffering from hypercapnic respiratory failure secondary to an acute COPD exacerbation, as evidenced by elevated PaCO2 (58 mmHg, rising to 62 mmHg) and decreased pH (7.31, falling to 7.29) despite maximal conventional therapy and initiation of BiPAP. The patient is alert and cooperative, tolerating the mask, which suggests that non-invasive ventilation (NIV) is a viable option to pursue further.\n\nThe current BiPAP settings are IPAP 12/EPAP 5 cm H2O. This provides a pressure support of 7 cm H2O (IPAP - EPAP). The lack of improvement in PaCO2 and pH indicates that the minute ventilation achieved with these settings is insufficient.\n\nLet's evaluate the options:\n\nA. Increase IPAP to 18 cm H2O and reassess in 1-2 hours: Increasing IPAP directly increases the tidal volume delivered during inspiration, thereby increasing minute ventilation and improving CO2 removal. Increasing IPAP from 12 to 18 cm H2O will increase the pressure support to 13 cm H2O (18-5), which is a substantial increase. This is a reasonable strategy to optimize NIV before considering escalation to invasive ventilation, especially since the patient is alert and tolerating the mask.\n\nB. Proceed with endotracheal intubation and mechanical ventilation: Intubation is indicated if NIV fails, the patient deteriorates significantly (e.g., obtundation, hemodynamic instability, severe hypoxemia refractory to NIV), or if there are contraindications to NIV. While the ABGs are not improving, the patient is alert and cooperative, tolerating the mask. Optimizing NIV is the preferred next step.\n\nC. Add heliox (helium-oxygen mixture) to the BiPAP circuit: Heliox is used to reduce airflow resistance in conditions like upper airway obstruction or severe bronchospasm. While COPD patients have bronchospasm, heliox is not a standard adjunctive therapy for hypercapnic respiratory failure managed with BiPAP, and its benefit in this specific scenario is not well-established compared to optimizing BiPAP settings.\n\nD. Switch to high-flow nasal cannula at 60 L/min: High-flow nasal cannula (HFNC) can provide some positive pressure, improve oxygenation, and reduce dead-space ventilation. However, it is generally less effective than BiPAP in generating sufficient positive pressure to counteract hypercapnia and improve ventilation in significant respiratory failure. BiPAP offers more targeted ventilatory support.\n\nE. Increase EPAP to 10 cm H2O while maintaining IPAP: Increasing EPAP primarily improves oxygenation by increasing functional residual capacity and recruiting alveoli. However, it also increases the work of breathing during expiration and can reduce tidal volume if not compensated by increased IPAP. Given the primary problem is hypercapnia and inadequate ventilation, increasing EPAP alone is unlikely to be the most effective next step and could potentially worsen ventilation if IPAP is not also adjusted sufficiently. The current EPAP of 5 is reasonable for COPD.\n\nTherefore, the most appropriate next step is to optimize the current NIV by increasing the inspiratory pressure support.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-003", "question": "A 45-year-old woman from rural Peru presents with a 3-month history of progressive dysphagia, regurgitation, and 20-pound weight loss. Barium swallow shows a dilated esophagus with smooth tapering at the gastroesophageal junction (\"bird's beak\" appearance). Esophageal manometry reveals absent peristalsis and incomplete lower esophageal sphincter relaxation. Serologic testing for Trypanosoma cruzi is positive. Cardiac evaluation shows a dilated left ventricle with apical aneurysm and EF 35%. Which statement best characterizes the pathophysiology linking her esophageal and cardiac findings?", "options": ["Direct parasitic invasion of smooth muscle cells in both organs", "Autoimmune destruction of intramural neurons and cardiac myocytes", "Eosinophilic infiltration causing tissue fibrosis", "Vasculitis affecting the vasa nervorum and coronary arteries", "Toxin-mediated damage similar to diphtheria"], "answer": "B", "answer_index": 1, "explanation": "Chronic Chagas disease (American trypanosomiasis) causes megaesophagus and cardiomyopathy through autoimmune mechanisms. Molecular mimicry between T. cruzi antigens and host cardiac myosin, neuronal proteins, and other self-antigens triggers autoimmune destruction of intramural ganglion cells (Auerbach's plexus) in the esophagus and cardiac myocytes/conduction tissue. The apical aneurysm is pathognomonic for Chagas cardiomyopathy. Direct parasitic invasion occurs in acute phase but parasites are rarely found in chronic lesions. The pathology is characterized by lymphocytic infiltration and fibrosis, not eosinophilia or vasculitis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "target_topic", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-015", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "B", "model_outputs": "The patient presents with symptoms and findings highly suggestive of Chagas disease: progressive dysphagia leading to megaesophagus (indicated by dilated esophagus, smooth tapering at GE junction on barium swallow, and manometry showing absent peristalsis and incomplete LES relaxation) and Chagasic cardiomyopathy (dilated left ventricle, apical aneurysm, reduced EF). The positive serology for *Trypanosoma cruzi* confirms the diagnosis.\n\nThe pathophysiology of chronic Chagas disease, including megaesophagus and cardiomyopathy, is complex but is largely considered to be immune-mediated rather than solely due to direct parasite invasion in the chronic phase. *Trypanosoma cruzi* infects cells, including neurons and myocytes, but the progressive, debilitating damage in the chronic stage is thought to arise from a combination of factors:\n1.  Inflammation: Chronic inflammatory infiltrates are found in affected organs.\n2.  Neuronal damage: Destruction of autonomic ganglion cells within the myenteric plexus of the gastrointestinal tract and the cardiac conduction system. This denervation leads to aperistalsis and failure of sphincter relaxation (megaesophagus/achalasia) and arrhythmias/conduction defects (cardiac).\n3.  Autoimmunity: This is a leading hypothesis for the chronic, progressive damage. It's proposed that host immune responses, potentially triggered by molecular mimicry between parasite antigens and host tissues (neuronal and cardiac proteins), lead to the autoimmune destruction of these host cells, including intramural neurons and cardiac myocytes.\n\nLet's examine the options in light of this understanding:\n\nA.  Direct parasitic invasion of smooth muscle cells in both organs: While direct invasion occurs, especially in the acute phase, it's not the primary driver of chronic damage in megaesophagus and cardiomyopathy. The damage is more complex and involves neuronal and immune mechanisms.\nB.  Autoimmune destruction of intramural neurons and cardiac myocytes: This option accurately reflects the current understanding of Chagasic pathophysiology. Damage to intramural neurons causes the esophageal dysfunction, and both neuronal damage and autoimmune attack on cardiac myocytes contribute to cardiomyopathy.\nC.  Eosinophilic infiltration causing tissue fibrosis: While inflammation and fibrosis are present in Chagasic organs, eosinophilic infiltration is not the specific or primary mechanism identified as the main cause of the extensive neuronal and myocyte damage.\nD.  Vasculitis affecting the vasa nervorum and coronary arteries: Vasculitis can be a feature in some infectious diseases, but it is not considered the predominant mechanism in Chagasic cardiomyopathy or megaesophagus. The primary damage is to the nerves and muscle cells themselves.\nE.  Toxin-mediated damage similar to diphtheria: *Trypanosoma cruzi* does not produce a toxin comparable to diphtheria toxin, which directly damages host tissues.\n\nTherefore, autoimmune destruction of intramural neurons and cardiac myocytes best characterizes the pathophysiology linking the esophageal and cardiac findings in this patient.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-004", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "topics_mapped", "source_label_raw": "Pediatrics", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed126.jsonl", "pred": "B", "model_outputs": "The neonate presents with d-transposition of the great arteries (d-TGA) with an intact ventricular septum (IVS). This condition leads to a separation of the pulmonary and systemic circulations, requiring adequate mixing of oxygenated and deoxygenated blood to maintain systemic oxygenation. Prostaglandin E1 is administered to keep the ductus arteriosus (DA) open, promoting some mixing between the pulmonary and systemic circuits. In this case, despite Prostaglandin E1 infusion, the neonate remains cyanotic with an oxygen saturation of 55%, indicating inadequate mixing. Echocardiography reveals a restrictive patent foramen ovale (PFO), which is the bottleneck and the cause of poor interatrial mixing. Oxygen is unresponsive, and Prostaglandin E1 is not sufficient to improve oxygenation. The infant is hemodynamically stable.\n\nThe goal is to improve oxygenation by increasing mixing.\n*   A. Emergent arterial switch operation: This is the definitive surgical repair for d-TGA. While necessary, it is not always the immediate *next* step if there is a readily correctable issue that can stabilize the patient and buy time for definitive surgery.\n*   B. Balloon atrial septostomy (BAS): This is a catheter-based procedure that creates or enlarges an atrial septal defect, improving the flow of oxygenated blood from the left atrium (pulmonary venous return) to the right atrium (systemic venous return). This directly addresses the restrictive PFO and is the standard interventional management for d-TGA with severe hypoxemia due to a restrictive atrial septum. It is typically performed urgently to stabilize the neonate before definitive surgical repair.\n*   C. Extracorporeal membrane oxygenation (ECMO): ECMO is a form of life support for severe cardiorespiratory failure. The infant is described as hemodynamically stable, so ECMO is not the most appropriate next step; it would be considered if other measures fail.\n*   D. Inhaled nitric oxide therapy: This is a selective pulmonary vasodilator used for pulmonary hypertension and does not address intracardiac mixing defects in TGA. It could potentially worsen hypoxemia in certain scenarios of TGA.\n*   E. Atrial septectomy via median sternotomy: This is an open surgical approach to create an atrial septal defect. While effective, it is more invasive than BAS and BAS is generally preferred as the initial intervention due to its less invasive nature and ability to quickly improve oxygenation.\n\nGiven the restrictive PFO and persistent severe cyanosis despite Prostaglandin E1, the most appropriate next step is to improve interatrial mixing. Balloon atrial septostomy (BAS) is the procedure of choice for this indication. It is less invasive than open surgery and is highly effective in stabilizing neonates with d-TGA and poor mixing.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-005", "question": "A 48-year-old woman is brought to the emergency department after being found unresponsive at home. She has a history of depression. On examination, she is comatose with pinpoint pupils, respiratory rate of 6/min, temperature 35.8°C, and blood pressure 90/60 mmHg. ECG shows QRS duration of 145 ms with a terminal R wave in aVR of 4 mm. After securing the airway and administering naloxone without response, what is the most appropriate next intervention?", "options": ["Intravenous flumazenil 0.2 mg", "Intravenous sodium bicarbonate bolus targeting serum pH 7.50-7.55", "Intravenous lipid emulsion 20% bolus", "Intravenous glucagon 5 mg bolus", "Emergent hemodialysis"], "answer": "B", "answer_index": 1, "explanation": "The clinical presentation (coma, miosis, respiratory depression, hypotension) with ECG findings of QRS widening >100 ms and terminal R wave in aVR >3 mm is classic for tricyclic antidepressant (TCA) toxicity. The sodium channel blockade causing cardiac toxicity is treated with sodium bicarbonate, which increases extracellular sodium (overcoming channel blockade) and alkalinizes serum (increasing protein binding of TCA). Target pH is 7.50-7.55. Flumazenil (A) is contraindicated as it may precipitate seizures in TCA overdose. Lipid emulsion (C) is second-line. Glucagon (D) is for beta-blocker toxicity. Hemodialysis (E) is ineffective for TCAs due to high protein binding and large volume of distribution.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Emergency Medicine", "abms_specialty": "Emergency Medicine", "abms_source": "topics_mapped", "source_label_raw": "Emergency Medicine", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "B", "model_outputs": "The patient presents with a constellation of symptoms and signs suggestive of a toxic overdose.\nKey findings:\n1.  Comatose state and respiratory depression (RR 6/min): Indicates significant central nervous system depression.\n2.  Pinpoint pupils: Classically associated with opioid overdose, but can also be seen in organophosphate poisoning or pontine hemorrhage, or sometimes with high doses of TCAs.\n3.  Hypotension (90/60 mmHg): A common complication of various overdoses, including opioids, TCAs, and others.\n4.  Hypothermia (35.8°C): CNS depression can impair thermoregulation.\n5.  ECG findings: Marked QRS widening (145 ms) and a terminal R wave in aVR (4 mm). These are highly specific indicators of tricyclic antidepressant (TCA) overdose. The QRS duration >100-120 ms and the R wave in aVR are predictors of increased risk for seizures and arrhythmias (e.g., ventricular tachycardia, torsades de pointes).\n6.  History of depression: Makes TCA overdose a highly probable etiology.\n7.  Naloxone administered without response: This makes pure opioid overdose unlikely or at least not the sole cause of the symptoms. However, co-ingestion is possible.\n\nConsidering these findings, TCA overdose is the leading diagnosis that explains the neurological depression, hypotension, and especially the characteristic ECG changes.\n\nNow evaluating the options:\nA.  Intravenous flumazenil 0.2 mg: Flumazenil is a benzodiazepine antagonist. While benzodiazepines can cause CNS and respiratory depression, they do not typically cause significant QRS widening or the specific ECG changes seen in the aVR lead suggestive of TCA toxicity. In a patient with suspected TCA overdose, flumazenil can precipitate seizures, making it contraindicated.\nB.  Intravenous sodium bicarbonate bolus targeting serum pH 7.50-7.55: Sodium bicarbonate is the first-line treatment for cardiotoxicity due to TCAs. It helps to reverse the sodium channel blockade caused by TCAs by increasing serum sodium and pH, thereby improving QRS duration and reducing the risk of arrhythmias. The ECG findings presented are a strong indication for this intervention.\nC.  Intravenous lipid emulsion 20% bolus: Lipid emulsion is primarily used for local anesthetic systemic toxicity (LAST) and certain other lipophilic drug overdoses (e.g., calcium channel blockers, beta-blockers, some antidepressants). While TCAs are lipophilic and lipid emulsion can be effective in severe cases, it is generally considered a second-line treatment after sodium bicarbonate for TCA cardiotoxicity, especially if there are signs of refractory hypotension or ventricular arrhythmias. Given the prominent ECG changes indicating potential cardiotoxicity, sodium bicarbonate is the more immediate and appropriate first step.\nD.  Intravenous glucagon 5 mg bolus: Glucagon is indicated for beta-blocker and calcium channel blocker overdose, not TCA overdose.\nE.  Emergent hemodialysis: Hemodialysis is generally ineffective for TCA overdose due to the drug's high protein binding and large volume of distribution. It is not a standard treatment.\n\nBased on the strong evidence of TCA toxicity from the ECG findings and history, sodium bicarbonate is the most appropriate next intervention.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-006", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Obstetrics and Gynecology", "abms_specialty": "Obstetrics and Gynecology", "abms_source": "topics_mapped", "source_label_raw": "obstetrics", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed126.jsonl", "pred": "B", "model_outputs": "The patient presents with severe preeclampsia, pulmonary edema, preserved ejection fraction (65%), grade III diastolic dysfunction, elevated E/e' ratio (18), and a low central venous pressure (CVP) of 4 mmHg.\n\nLet's analyze each option:\nA. Systolic heart failure from peripartum cardiomyopathy: The preserved ejection fraction of 65% makes significant systolic heart failure unlikely. Peripartum cardiomyopathy typically presents with reduced ejection fraction.\n\nB. Increased pulmonary capillary permeability from endothelial dysfunction: Severe preeclampsia is characterized by widespread endothelial dysfunction. This damage to the capillary endothelium increases vascular permeability, allowing fluid and proteins to leak from the capillaries into the interstitial space and alveoli, leading to pulmonary edema. This is a well-recognized mechanism of pulmonary edema in preeclampsia.\n\nC. Volume overload from iatrogenic fluid administration: The central venous pressure (CVP) of 4 mmHg is low to normal. This does not strongly suggest significant volume overload as the primary cause of pulmonary edema. While fluid administration can contribute, it's less likely to be the *best* explanation given the low CVP.\n\nD. Diastolic dysfunction from acute afterload mismatch: The patient has grade III diastolic dysfunction and an elevated E/e' ratio of 18, indicating significantly elevated left ventricular filling pressures. Severe preeclampsia is associated with high systemic vascular resistance (afterload). This increased afterload can impair left ventricular relaxation and diastolic filling, leading to increased left atrial and pulmonary venous pressures, which can cause hydrostatic pulmonary edema. This is a plausible mechanism.\n\nE. Mitral regurgitation from papillary muscle dysfunction: There is no mention of mitral regurgitation in the vignette, such as a murmur or signs suggestive of it. While possible in severe preeclampsia, it's not the primary finding presented.\n\nComparing options B and D:\nBoth diastolic dysfunction (leading to elevated filling pressures causing hydrostatic edema) and endothelial dysfunction (leading to increased permeability and non-hydrostatic edema) can contribute to pulmonary edema in severe preeclampsia. However, preeclampsia is fundamentally a disease of endothelial dysfunction, which causes widespread vascular damage and increased permeability. This increased permeability is a critical factor that makes the lungs prone to edema, often exacerbating edema caused by elevated hydrostatic pressures. The pulmonary edema in preeclampsia is considered multifactorial, involving both increased hydrostatic pressure (due to hypertension and diastolic dysfunction) and increased capillary permeability. Given that severe preeclampsia itself is defined by endothelial dysfunction, and this dysfunction directly compromises vascular integrity and promotes fluid leakage, option B represents a core pathophysiologic mechanism of the disease that directly leads to pulmonary edema. The low CVP also subtly supports the idea that fluid might be leaking out of vessels rather than just pooling due to systemic overload.\n\nTherefore, increased pulmonary capillary permeability due to endothelial dysfunction is considered a primary driver of pulmonary edema in severe preeclampsia.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-007", "question": "A 35-year-old woman with no psychiatric history presents with acute onset of bizarre behavior, visual hallucinations, and seizures over 3 days. She has no fever. MRI brain shows bilateral medial temporal lobe T2 hyperintensities. CSF analysis reveals lymphocytic pleocytosis (45 cells/μL), elevated protein (68 mg/dL), and normal glucose. EEG shows extreme delta brush pattern. Anti-NMDA receptor antibodies return positive in CSF. CT of chest, abdomen, and pelvis reveals a 4-cm right ovarian mass. After tumor resection (pathology confirms ovarian teratoma), she receives first-line immunotherapy with high-dose corticosteroids, IVIG, and plasmapheresis. At week 6, she remains comatose with persistent seizures. Which of the following is the most appropriate next step in management?", "options": ["Continue current immunotherapy regimen for additional 6 weeks", "Initiate rituximab 375 mg/m² weekly for 4 doses", "Initiate cyclophosphamide 750 mg/m² monthly", "Initiate rituximab and cyclophosphamide combination therapy", "Initiate intrathecal methotrexate"], "answer": "D", "answer_index": 3, "explanation": "Anti-NMDA receptor encephalitis refractory to first-line therapy (tumor removal, corticosteroids, IVIG, and/or plasmapheresis) requires escalation to second-line immunotherapy. Current evidence and expert consensus support combination rituximab and cyclophosphamide as second-line therapy for refractory cases, as this combination targets both B-cell mediated antibody production and provides broader immunosuppression. Using either agent alone is less effective in severe refractory cases. Continuing first-line therapy alone when there is no response at 6 weeks delays effective treatment. Intrathecal methotrexate is not standard therapy for autoimmune encephalitis.", "generator_model": "claude-opus-4-5-20251101", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "abms_specialty": "Psychiatry", "abms_source": "target_topic", "source_label_raw": "Psychiatry", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128-015", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed128.jsonl", "pred": "D", "model_outputs": "The patient presents with anti-NMDA receptor encephalitis. First-line treatment, consisting of tumor resection (ovarian teratoma), high-dose corticosteroids, IVIG, and plasmapheresis, has been administered. At week 6, the patient remains comatose with persistent seizures, indicating a lack of response to initial therapy. This signifies a severe and refractory form of the disease, necessitating second-line immunotherapy.\n\nSecond-line treatment options for refractory anti-NMDA receptor encephalitis include rituximab, cyclophosphamide, azathioprine, mycophenolate mofetil, or combination immunosuppression.\n\nOption A is incorrect because continuing the same regimen without response is not appropriate.\nOption E is incorrect because intrathecal methotrexate is not indicated for autoimmune encephalitis.\n\nWe are left with options B, C, and D.\nOption B (rituximab) is a standard and often preferred second-line treatment due to its targeted action against B cells, which are responsible for producing autoantibodies.\nOption C (cyclophosphamide) is another recognized immunosuppressant used as second-line therapy.\nOption D (combination of rituximab and cyclophosphamide) represents a more aggressive immunosuppressive strategy. Literature indicates that combination therapy is often used for severe and refractory cases.\n\nGiven that the patient remains comatose with persistent seizures after 6 weeks, the disease is both severe and refractory. In such scenarios, escalating immunosuppression more aggressively to achieve a rapid and profound response is often considered the most appropriate next step. Combination therapy with rituximab and cyclophosphamide offers broader and potentially deeper immunosuppression compared to monotherapy. Therefore, initiating combination therapy is a reasonable and often recommended strategy for severe refractory anti-NMDA receptor encephalitis.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-008", "question": "A 62-year-old man with longstanding type 2 diabetes presents with a 6-month history of burning pain and numbness in his feet, now extending to mid-calf. Examination reveals absent ankle reflexes, reduced pinprick and vibration sense to the knees bilaterally, and mild weakness of toe extension. Nerve conduction studies show absent sural sensory responses, reduced peroneal motor amplitudes with mildly slowed conduction velocities, and prolonged F-wave latencies. Hemoglobin A1c is 7.2%. He is started on duloxetine with minimal improvement after 8 weeks. Gabapentin is added and titrated to 1800 mg daily with partial response. Which additional intervention has the strongest evidence for further symptomatic improvement?", "options": ["Alpha-lipoic acid 600 mg IV daily for 3 weeks", "Topical capsaicin 8% patch application to affected areas", "Spinal cord stimulation trial", "Transcutaneous electrical nerve stimulation (TENS)", "Acupuncture twice weekly for 12 weeks"], "answer": "C", "answer_index": 2, "explanation": "This patient has painful diabetic peripheral neuropathy refractory to first-line (duloxetine) and second-line (gabapentin) pharmacotherapy. Spinal cord stimulation (SCS) has Level 1 evidence from randomized controlled trials (SENZA-PDN, others) demonstrating significant pain reduction in refractory painful diabetic neuropathy, with FDA approval for this indication. Alpha-lipoic acid (A) has modest evidence primarily from European studies. High-concentration capsaicin (B) provides temporary relief but evidence in diabetic neuropathy is limited. TENS (D) and acupuncture (E) have weaker evidence compared to SCS for refractory cases.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "abms_specialty": "Neurology", "abms_source": "topics_mapped", "source_label_raw": "Neurology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "B", "model_outputs": "The patient presents with symptoms and objective findings consistent with distal symmetric polyneuropathy due to long-standing type 2 diabetes. He has already been treated with duloxetine with minimal improvement and gabapentin with partial response. The question asks for an additional intervention with the strongest evidence for further symptomatic improvement.\n\nLet's evaluate the options:\n\nA. Alpha-lipoic acid 600 mg IV daily for 3 weeks: Alpha-lipoic acid, particularly the oral form, has moderate evidence supporting its use in reducing symptoms of diabetic neuropathy. Intravenous administration may lead to quicker or more pronounced effects, but the optimal duration for sustained relief and the evidence compared to other adjunctive therapies needs consideration.\n\nB. Topical capsaicin 8% patch application to affected areas: High-concentration (8%) topical capsaicin patches are a well-established and evidence-based treatment for localized neuropathic pain, including painful diabetic neuropathy. Clinical trials and meta-analyses consistently show significant pain reduction when used as an adjunctive therapy after systemic agents have provided suboptimal relief. The 8% patch specifically targets C-fiber afferent nerves and provides localized relief.\n\nC. Spinal cord stimulation trial: Spinal cord stimulation is a more invasive procedure typically reserved for severe, refractory neuropathic pain that has not responded to multiple medical and interventional therapies. While it can be effective, it is not usually considered as a first or second-line adjunctive therapy for standard diabetic neuropathy pain, and the evidence base for its specific efficacy in DPN might be less robust than for other options.\n\nD. Transcutaneous electrical nerve stimulation (TENS): TENS is a non-invasive modality with mixed evidence for the treatment of painful diabetic neuropathy. While some patients may experience relief, the evidence for its consistent efficacy is generally considered weaker than for pharmacological agents or high-concentration topical treatments.\n\nE. Acupuncture twice weekly for 12 weeks: Acupuncture is a complementary therapy. Some studies suggest it can be beneficial for chronic pain, including DPN. However, the quality of evidence is often moderate, and its effectiveness can be variable. Evidence for acupuncture in DPN is generally not considered as strong or as consistently replicated as for capsaicin or alpha-lipoic acid.\n\nComparing the options, topical capsaicin 8% patch has strong evidence as an effective adjunctive therapy for symptomatic relief of painful diabetic neuropathy when initial pharmacotherapy has not provided adequate control. Given the patient's partial response to duloxetine and gabapentin, the 8% capsaicin patch represents an excellent option with substantial evidence for further symptomatic improvement.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-009", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "topics_mapped", "source_label_raw": "Pediatrics", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed126.jsonl", "pred": "D", "model_outputs": "The patient presents with a classic history of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) syndrome. The recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2, with resolution within 5 days and complete well-being between episodes, are hallmark features. The elevated CRP and ESR during episodes, along with normal growth, are also consistent with PFAPA. The negative genetic testing for FMF, TRAPS, and HIDS further supports PFAPA as the diagnosis, as it is a diagnosis of exclusion and mutations in these syndromes are not found in PFAPA.\n\nNow let's evaluate the treatment options for inducing complete remission:\n\nA. Colchicine prophylaxis: While sometimes used for PFAPA, its efficacy in inducing complete remission is variable and generally considered less potent than other options.\n\nB. Anakinra during episodes: Anakinra is an IL-1 receptor antagonist that is highly effective in aborting acute episodes of PFAPA and reducing symptom severity. However, it is typically used for acute management, and while it can lead to symptom-free periods, it is not considered a definitive cure for complete remission in the same way as surgical intervention.\n\nC. Single-dose corticosteroid at episode onset: Corticosteroids are very effective at aborting an acute episode and can lead to prolonged symptom-free intervals (months). Some patients may experience remission after a course of steroids, but recurrence after the steroid effect wears off is common, and it's not considered curative in the long term for all patients.\n\nD. Tonsillectomy with or without adenoidectomy: This surgical intervention is widely recognized as the most effective treatment for PFAPA, with reported remission rates exceeding 80-90%. It is considered curative for the vast majority of patients, leading to the highest likelihood of complete and lasting remission.\n\nE. Cimetidine prophylaxis: While some studies suggest potential benefit, cimetidine is generally considered less effective and less consistently used for PFAPA compared to steroids, biologics, or tonsillectomy.\n\nComparing the options for inducing *complete remission*, tonsillectomy stands out as the treatment with the highest likelihood of achieving this outcome.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-010", "question": "A 6-year-old boy presents with recurrent episodes of weakness and dark urine following viral illnesses. Laboratory studies during an acute episode show: serum creatine kinase 45,000 U/L, myoglobinuria, and non-ketotic hypoglycemia with inappropriately low free fatty acids. Acylcarnitine profile shows elevated C14:1 and C14:2 species. Genetic testing confirms compound heterozygous mutations in ACADVL. Which of the following dietary modifications is most critical for preventing future metabolic crises?", "options": ["Strict avoidance of medium-chain triglycerides", "Supplementation with odd-chain fatty acids", "Restriction of long-chain fatty acids with medium-chain triglyceride supplementation", "High-protein diet with branched-chain amino acid supplementation", "Carnitine supplementation with unrestricted fat intake"], "answer": "C", "answer_index": 2, "explanation": "ACADVL mutations cause very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, a disorder of long-chain fatty acid oxidation. Management requires restriction of long-chain fatty acids (which cannot be metabolized) and supplementation with medium-chain triglycerides (MCTs), which bypass the defective enzyme and provide an alternative energy source. MCT avoidance would be harmful. Carnitine supplementation alone without dietary modification is insufficient, and high-protein diets do not address the underlying metabolic defect.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "topics_mapped", "source_label_raw": "Pediatrics", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed127", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed127.jsonl", "pred": "C", "model_outputs": "The patient presents with symptoms and laboratory findings highly suggestive of Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) deficiency. This is confirmed by the genetic testing showing mutations in ACADVL, the gene encoding the VLCAD enzyme. VLCAD is crucial for the beta-oxidation of very long-chain fatty acids (typically C14 and longer, especially odd-numbered unsaturated ones like C14:1 and C14:2 which are elevated in the acylcarnitine profile).\n\nDuring metabolic stress (like viral illnesses) or fasting, the body relies on fatty acid oxidation for energy. In VLCAD deficiency, this pathway is impaired, leading to energy deficiency, hypoglycemia, muscle breakdown (high CK, myoglobinuria), and accumulation of toxic intermediates.\n\nThe management strategies for fatty acid oxidation disorders (FAODs) aim to provide alternative energy sources and avoid overwhelming the defective pathway. Let's analyze the options:\n\nA.  Strict avoidance of medium-chain triglycerides (MCTs): MCTs (C6-C12) are oxidized independently of the VLCAD pathway. They are readily used for energy and are a cornerstone of nutritional management in many LCFA oxidation defects. Avoiding them would be detrimental.\n\nB.  Supplementation with odd-chain fatty acids: While odd-chain fatty acids can be catabolized, their inclusion is not a primary strategy for managing VLCAD deficiency. The focus is on managing even-chain fatty acids and providing alternative fuels.\n\nC.  Restriction of long-chain fatty acids with medium-chain triglyceride supplementation: This is the cornerstone of management for VLCAD deficiency. Restricting very long-chain fatty acids reduces the burden on the defective enzyme. Supplementing with MCTs provides a readily available energy source that bypasses the VLCAD pathway defect, preventing hypoglycemia and muscle breakdown. This is the most critical dietary modification.\n\nD.  High-protein diet with branched-chain amino acid supplementation: This is not the primary management for FAODs. The issue is fat metabolism, so providing alternative energy sources like carbohydrates and MCTs, rather than relying on protein which can also be metabolically taxing, is preferred.\n\nE.  Carnitine supplementation with unrestricted fat intake: Carnitine supplementation is indicated for defects in carnitine transport or conjugation, which are upstream of the enzyme defect itself. While some patients with VLCAD deficiency might have secondary carnitine deficiency, the primary problem is the enzyme's function. Crucially, unrestricted fat intake (especially long-chain) would be dangerous as the body cannot oxidize these fats effectively.\n\nTherefore, restricting LCFA and supplementing with MCTs is the most critical dietary modification.\n\nThe final answer is $\\boxed{C}$."}]